APO Research
Talk to an analyst

APO RESEARCH · REPORT

DPP-4 Inhibitors for Type 2 Diabetes Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Outlook and Growth Opportunities 2026

30 December 2025190 pages

Choose your research edition.

Industry ResearchDPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global DPP-4 Inhibitors for Type 2 Diabetes Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the DPP-4 Inhibitors for Type 2 Diabetes Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the DPP-4 Inhibitors for Type 2 Diabetes Treatment market include Novartis, Merck, Eli Lilly and Company, AstraZeneca, Takeda Pharmaceutical, Sanwa Kagaku Kenkyusho, Mitsubishi Tanabe Pharma, LG Life Sciences and Dong-A Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global DPP-4 Inhibitors for Type 2 Diabetes Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of DPP-4 Inhibitors for Type 2 Diabetes Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents DPP-4 Inhibitors for Type 2 Diabetes Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the DPP-4 Inhibitors for Type 2 Diabetes Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Company

Novartis

Merck

Eli Lilly and Company

AstraZeneca

Takeda Pharmaceutical

Sanwa Kagaku Kenkyusho

Mitsubishi Tanabe Pharma

LG Life Sciences

Dong-A Pharmaceuticals

Bristol-Myers Squibb

Boehringer Ingelheim

DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Type

Alogliptin

Linagliptin

Saxagliptin

Vildagliptin

Sitagliptin

Others

DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Application

Hospitals and Clinics

Offline Retail Pharmacy

E-commerce and Internet Medical Care

DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global DPP-4 Inhibitors for Type 2 Diabetes Treatment status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions DPP-4 Inhibitors for Type 2 Diabetes Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify DPP-4 Inhibitors for Type 2 Diabetes Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze DPP-4 Inhibitors for Type 2 Diabetes Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DPP-4 Inhibitors for Type 2 Diabetes Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of DPP-4 Inhibitors for Type 2 Diabetes Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DPP-4 Inhibitors for Type 2 Diabetes Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the DPP-4 Inhibitors for Type 2 Diabetes Treatment market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global DPP-4 Inhibitors for Type 2 Diabetes Treatment industry.

Chapter 3: Detailed analysis of DPP-4 Inhibitors for Type 2 Diabetes Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of DPP-4 Inhibitors for Type 2 Diabetes Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of DPP-4 Inhibitors for Type 2 Diabetes Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Trends Table 2. DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Drivers Table 3. DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Opportunities and Challenges Table 4. DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Restraints Table 5. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Company (2021-2026) Table 7. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Company (M Pcs) & (2021-2026) Table 8. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Company (2021-2026) Table 9. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Average Price (US$/K Pcs) of Company (2021-2026) Table 10. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Company Ranking, (2024-2026) & (USD Million) Table 11. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Key Company Manufacturing Base & Headquarters Table 12. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Company, Product Type & Application Table 13. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Alogliptin Table 18. Significant Companies of Linagliptin Table 19. Significant Companies of Saxagliptin Table 20. Significant Companies of Vildagliptin Table 21. Significant Companies of Sitagliptin Table 22. Significant Companies of Others Table 23. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Type 2021 VS 2025 VS 2032 (M Pcs) Table 24. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Type (2021-2026) & (M Pcs) Table 25. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Type (2027-2032) & (M Pcs) Table 26. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Type (2021-2026) Table 27. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Type (2027-2032) Table 28. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type (2021-2026) Table 32. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Hospitals and Clinics Table 34. Significant Companies of Offline Retail Pharmacy Table 35. Significant Companies of E-commerce and Internet Medical Care Table 36. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Application 2021 VS 2025 VS 2032 (M Pcs) Table 37. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Application (2021-2026) & (M Pcs) Table 38. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Application (2027-2032) & (M Pcs) Table 39. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Application (2021-2026) Table 40. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Application (2027-2032) Table 41. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application (2021-2026) Table 45. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application (2027-2032) Table 46. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2021 VS 2025 VS 2032 (M Pcs) Table 47. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2021-2026) & (M Pcs) Table 48. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2021-2026) Table 49. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2027-2032) & (M Pcs) Table 50. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2027-2032) Table 51. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Region (2021-2026) Table 54. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Region (2027-2032) Table 56. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Average Price (US$/K Pcs) by Region (2021-2026) Table 57. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Average Price (US$/K Pcs) by Region (2027-2032) Table 58. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country: 2021 VS 2025 VS 2032 (M Pcs) Table 59. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 61. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2026) Table 62. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2027-2032) & (M Pcs) Table 63. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2027-2032) Table 64. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Market Share by Country (2021-2026) Table 66. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Market Share by Country (2027-2032) Table 68. Novartis Company Information Table 69. Novartis Business Overview Table 70. Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 71. Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 72. Novartis Recent Development Table 73. Merck Company Information Table 74. Merck Business Overview Table 75. Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 76. Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 77. Merck Recent Development Table 78. Eli Lilly and Company Company Information Table 79. Eli Lilly and Company Business Overview Table 80. Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 81. Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 82. Eli Lilly and Company Recent Development Table 83. AstraZeneca Company Information Table 84. AstraZeneca Business Overview Table 85. AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 86. AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 87. AstraZeneca Recent Development Table 88. Takeda Pharmaceutical Company Information Table 89. Takeda Pharmaceutical Business Overview Table 90. Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 91. Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 92. Takeda Pharmaceutical Recent Development Table 93. Sanwa Kagaku Kenkyusho Company Information Table 94. Sanwa Kagaku Kenkyusho Business Overview Table 95. Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 96. Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 97. Sanwa Kagaku Kenkyusho Recent Development Table 98. Mitsubishi Tanabe Pharma Company Information Table 99. Mitsubishi Tanabe Pharma Business Overview Table 100. Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 101. Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 102. Mitsubishi Tanabe Pharma Recent Development Table 103. LG Life Sciences Company Information Table 104. LG Life Sciences Business Overview Table 105. LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 106. LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 107. LG Life Sciences Recent Development Table 108. Dong-A Pharmaceuticals Company Information Table 109. Dong-A Pharmaceuticals Business Overview Table 110. Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 111. Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 112. Dong-A Pharmaceuticals Recent Development Table 113. Bristol-Myers Squibb Company Information Table 114. Bristol-Myers Squibb Business Overview Table 115. Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 116. Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 117. Bristol-Myers Squibb Recent Development Table 118. Boehringer Ingelheim Company Information Table 119. Boehringer Ingelheim Business Overview Table 120. Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 121. Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 122. Boehringer Ingelheim Recent Development Table 123. Key Raw Materials Table 124. Raw Materials Key Suppliers Table 125. DPP-4 Inhibitors for Type 2 Diabetes Treatment Distributors List Table 126. DPP-4 Inhibitors for Type 2 Diabetes Treatment Customers List Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Image Figure 2. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032) & (US$ Million) Figure 4. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (2021-2032) & (M Pcs) Figure 5. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Average Price (US$/K Pcs) & (2021-2032) Figure 6. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Alogliptin Image Figure 10. Linagliptin Image Figure 11. Saxagliptin Image Figure 12. Vildagliptin Image Figure 13. Sitagliptin Image Figure 14. Others Image Figure 15. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Type (2021 VS 2025 VS 2032) & (M Pcs) Figure 16. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Type (2021-2032) Figure 18. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type (2021-2032) Figure 21. Hospitals and Clinics Image Figure 22. Offline Retail Pharmacy Image Figure 23. E-commerce and Internet Medical Care Image Figure 24. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Application (2021 VS 2025 VS 2032) & (M Pcs) Figure 25. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Application (2021-2032) Figure 27. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application (2021-2032) Figure 30. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2021 VS 2025 VS 2032 (M Pcs) Figure 31. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032) & (US$ Million) Figure 35. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032) & (US$ Million) Figure 37. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032) & (US$ Million) Figure 41. South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. DPP-4 Inhibitors for Type 2 Diabetes Treatment Value Chain Figure 129. Manufacturing Cost Structure Figure 130. DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Alogliptin
  • Linagliptin
  • Saxagliptin
  • Vildagliptin
  • Sitagliptin
  • Others
Applications
  • Hospitals and Clinics
  • Offline Retail Pharmacy
  • E-commerce and Internet Medical Care
Companies covered
  • Novartis
  • Merck
  • Eli Lilly and Company
  • AstraZeneca
  • Takeda Pharmaceutical
  • Sanwa Kagaku Kenkyusho
  • Mitsubishi Tanabe Pharma
  • LG Life Sciences
  • Dong-A Pharmaceuticals
  • Bristol-Myers Squibb
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032)
  4. 1.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume (2021-2032)
  5. 1.2.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Dynamics
  1. 2.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Trends
  2. 2.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Drivers
  3. 2.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Opportunities and Challenges
  4. 2.4 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Restraints
3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Company
  1. 3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Company Revenue Ranking in 2025
  2. 3.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Company (2021-2026)
  3. 3.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Company (2021-2026)
  4. 3.4 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Average Price by Company (2021-2026)
  5. 3.5 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Company Ranking (2024-2026)
  6. 3.6 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Company Manufacturing Base and Headquarters
  7. 3.7 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Company Product Type and Application
  8. 3.8 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 DPP-4 Inhibitors for Type 2 Diabetes Treatment Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Type
  1. 4.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Type Introduction
  2. 4.1.1 Alogliptin
  3. 4.1.2 Linagliptin
  4. 4.1.3 Saxagliptin
  5. 4.1.4 Vildagliptin
  6. 4.1.5 Sitagliptin
  7. 4.1.6 Others
  8. 4.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Type
  9. 4.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Type (2021-2032)
  11. 4.2.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Type (2021-2032)
  12. 4.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Type
  13. 4.3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Type (2021-2032)
  15. 4.3.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type (2021-2032)
5 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Application
  1. 5.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Application Introduction
  2. 5.1.1 Hospitals and Clinics
  3. 5.1.2 Offline Retail Pharmacy
  4. 5.1.3 E-commerce and Internet Medical Care
  5. 5.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Application
  6. 5.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Application (2021-2032)
  8. 5.2.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Application (2021-2032)
  9. 5.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Application
  10. 5.3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Application (2021-2032)
  12. 5.3.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application (2021-2032)
6 DPP-4 Inhibitors for Type 2 Diabetes Treatment Regional Sales and Value Analysis
  1. 6.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2021-2026
  4. 6.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2027-2032)
  5. 6.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Region (2021-2032)
  7. 6.4.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Region: 2021-2026
  8. 6.4.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Region (2027-2032)
  9. 6.5 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032)
  12. 6.6.2 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032)
  15. 6.7.2 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032)
  21. 6.9.2 South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country, 2025 VS 2032
7 DPP-4 Inhibitors for Type 2 Diabetes Treatment Country-level Sales and Value Analysis
  1. 7.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2032)
  4. 7.3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026)
  5. 7.3.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2027-2032)
  6. 7.4 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Country (2021-2032)
  7. 7.4.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Country (2021-2026)
  8. 7.4.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Eli Lilly and Company
  14. 8.3.1 Eli Lilly and Company Company Information
  15. 8.3.2 Eli Lilly and Company Business Overview
  16. 8.3.3 Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  18. 8.3.5 Eli Lilly and Company Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 Takeda Pharmaceutical
  26. 8.5.1 Takeda Pharmaceutical Company Information
  27. 8.5.2 Takeda Pharmaceutical Business Overview
  28. 8.5.3 Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  30. 8.5.5 Takeda Pharmaceutical Recent Developments
  31. 8.6 Sanwa Kagaku Kenkyusho
  32. 8.6.1 Sanwa Kagaku Kenkyusho Company Information
  33. 8.6.2 Sanwa Kagaku Kenkyusho Business Overview
  34. 8.6.3 Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  36. 8.6.5 Sanwa Kagaku Kenkyusho Recent Developments
  37. 8.7 Mitsubishi Tanabe Pharma
  38. 8.7.1 Mitsubishi Tanabe Pharma Company Information
  39. 8.7.2 Mitsubishi Tanabe Pharma Business Overview
  40. 8.7.3 Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  42. 8.7.5 Mitsubishi Tanabe Pharma Recent Developments
  43. 8.8 LG Life Sciences
  44. 8.8.1 LG Life Sciences Company Information
  45. 8.8.2 LG Life Sciences Business Overview
  46. 8.8.3 LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  48. 8.8.5 LG Life Sciences Recent Developments
  49. 8.9 Dong-A Pharmaceuticals
  50. 8.9.1 Dong-A Pharmaceuticals Company Information
  51. 8.9.2 Dong-A Pharmaceuticals Business Overview
  52. 8.9.3 Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  54. 8.9.5 Dong-A Pharmaceuticals Recent Developments
  55. 8.10 Bristol-Myers Squibb
  56. 8.10.1 Bristol-Myers Squibb Company Information
  57. 8.10.2 Bristol-Myers Squibb Business Overview
  58. 8.10.3 Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Recent Developments
  61. 8.11 Boehringer Ingelheim
  62. 8.11.1 Boehringer Ingelheim Company Information
  63. 8.11.2 Boehringer Ingelheim Business Overview
  64. 8.11.3 Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  66. 8.11.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Value Chain Analysis
  2. 9.1.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Mode & Process
  6. 9.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Distributors
  9. 9.2.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst